摘要
宫颈癌是在全球妇女中发病率位居第2位的恶性肿瘤，每年新发病人数约50万，死亡人数约23万，其中80％的宫颈癌发生在发展中国家。由于宫颈癌的发病与高危型人乳头状瘤病毒（HPV）感染密切相关，目前国际上对HPV疫苗的研究正在如火如荼地进行。
出处
《中华妇产科杂志》
CAS
CSCD
北大核心
2009年第12期950-952,共3页
Chinese Journal of Obstetrics and Gynecology
参考文献20
-
1Parkin DM, Bray F, Ferlay J, et al. Global cancer stastistics 2002. CA Cancer J Clin, 2005, 55: 74-108.
-
2Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 2002, 55:244-265.
-
3Kirnbauer R, Taub J, Greenstone H,et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol, 1993,67:6929-6936.
-
4zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer, 2002,2:342-350.
-
5Kanda T, Kondo K. Development of an HPV vaccine for a broad spectrum of high-risk types. Hum Vaccin, 2009, 5:43-45.
-
6Kawana K, Yasngi T, Kanda T, et ah Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine, 2003, 21:4256-4260.
-
7Tay EH, Garland S, Tang G, et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region, lnt J Gynaecol Obstet, 2008, 102:275- 283.
-
8Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine, 2007, 25:4931-4939.
-
9Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 2006, 367:1247-1255.
-
10Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent LI virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 2004, 364 : 1757-1765.
同被引文献17
-
1朱华,帅茨霞.年轻妇女宫颈癌134例初步分析[J].临床肿瘤学杂志,2004,9(4):383-385. 被引量：21
-
2王鲁平.人乳头状瘤病毒感染与子宫颈病变关系的研究进展及应对策略[J].诊断病理学杂志,2007,14(2):86-89. 被引量：47
-
3刘明君,张秀荣,刘婕.947例女性患者HPV感染与细胞学检查与分析[J].中外健康文摘,2001,8(7):49-50.
-
4Munoz N, Bosch FX, de-Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer[J]. N Engl J Med, 2003,348 (6) : 518- 527.
-
5Munoz N,Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The internatinal perspective [J ]. Int J Cancer, 2004,111(2):278-285.
-
6Ma YY,Wei SJ,Lin YC,et al. PIK3CA as an oncogene in cervical eancer [J ]. Oncogene, 2000, 19 (23): 2739-2744.
-
7Garcia-Echeverria C, Sellers WR. Drug discovery ap- proaches targeting the PI3K/Akt pathway in cancer[J]. Oncogene,2008,27(41) :5511-5526.
-
8Moseicki AB. HPV Vaccines: today and in the Future [J]. J Adolesc Health,2008,43(4 Suppl) : S26-40.
-
9Kanda T,Kondo K. Development of an HPV vaccine for a broad spectrum of high-risk types[J]. Hum Vaccin, 2009,5(1) :43-45.
-
10刘兰芳,孙海燕.831例35岁以下妇女宫颈癌的临床病理特点和预后[J].中国癌症杂志,2008,18(4):298-301. 被引量：37
二级引证文献3
-
1徐晓英,龙雯晴,王秀美,薛晓玲,卢红.改良冷刀锥切与LEEP治疗宫颈高级别上皮内瘤样病变的疗效比较[J].右江医学,2015,43(1):61-63. 被引量：2
-
2刘丽丽,刘丽燕,何焕群,赵正云.月经周期对妇女HPV检测结果的影响[J].医学临床研究,2015,32(11):2251-2253.
-
3曾白兰,张琴.HPV感染妇女健康教育现状与展望[J].中国医药科学,2020,10(14):51-53. 被引量：2
-
1胡超钰.宫颈癌疫苗的研究进展现状[J].深圳中西医结合杂志,2016,26(6):197-198.
-
2欧盟批准新一代宫颈癌疫苗上市[J].医药前沿,2015,5(28):1-1.
-
3刘剑勇,李挺.肿瘤疫苗的研究进展[J].中国医学文摘（肿瘤学）,2000,14(4):322-324. 被引量：1
-
4聂建梅,谷春霞,张振龙(综述).肿瘤疫苗的研究进展[J].国际生物制品学杂志,2011,34(2):86-90.
-
5张晓辉,孙强.乳腺癌疫苗的研究进展[J].中华临床医师杂志（电子版）,2012,6(12):134-135. 被引量：2
-
6吕方芳,洪小南,李进.树突状细胞疫苗研究进展[J].中国癌症杂志,2004,14(1):86-89. 被引量：1
-
7黄薇,李力,田厚文.子宫颈癌人乳头状瘤病毒疫苗的研究进展[J].国外医学（病毒学分册）,2003,10(3):70-74.
-
8阎玉英,樊婷婷.HPV疫苗的研究进展[J].首都医药,2012,19(4):23-24. 被引量：1
-
9吴勉云,伍欣星,邱惠.HPV相关肿瘤疫苗的研究进展[J].肿瘤防治杂志,2003,10(1):21-23. 被引量：2
-
10甄振华(综述),詹必红(审校),孙伟(审校).非小细胞肺癌分子标志物研究进展[J].肿瘤研究与临床,2011,23(8):570-574.
